Community pharmacists serve as the first point of contact for patients deciding whether to get vaccinated while managing chronic conditions or ongoing treatments. A rising number of medications—including immunosuppressants, corticosteroids, B-cell–depleting therapies, and some antivirals—can weaken the body’s response to vaccines. This leaves immunocompromised patients with reduced protection or forces last-minute changes to their vaccination schedules.
Timing vaccines around immunosuppressive therapy
Most disease-modifying antirheumatic drugs, biologics, chemotherapy agents, and transplant-related immunosuppressants lower the immune system’s ability to produce antibodies after vaccination. The impact depends on the drug, dosage, and treatment duration, but the outcome remains the same: patients vaccinated while immunosuppressed often develop fewer antibodies and may not achieve the same protection as healthy individuals.
Federal guidelines advise giving both live and nonlive vaccines at least two weeks before starting immunosuppressive treatment. If vaccination occurs during therapy, revaccination may be required once immune function recovers. Pharmacists can identify patients who would benefit from early vaccination, especially as biologics become more widely used for conditions like arthritis, gastrointestinal disorders, and skin diseases.
Corticosteroids: dose matters
High-dose systemic corticosteroids—defined as at least 20 mg of prednisone daily (or 2 mg/kg/day for patients weighing less than 10 kg) for 14 days or longer—can suppress immune function enough to raise concerns about vaccine safety and effectiveness. Patients on these regimens should typically delay live vaccines until at least a month after stopping therapy, while inactivated vaccines can be administered before treatment begins or postponed if possible.
Related: Health Canada OKs hot flash drug for cancer patients
Lower doses, short courses under 14 days, inhaled steroids, topical preparations, and intra-articular injections usually do not interfere with vaccination. This distinction is often missed, leading to unnecessary delays. Pharmacists can clarify these differences during medication reviews, ensuring patients do not skip vaccines without cause.
B-cell–depleting therapies create long-term gaps
Medications like rituximab and ocrelizumab target B lymphocytes, which play a key role in antibody production. Since B-cell depletion can persist for months after the last dose, patients on these therapies may have weaker responses to vaccines.
Guidelines recommend administering nonlive vaccines at least two weeks before starting anti–B-cell therapy. For those already undergoing treatment, vaccination is usually delayed until at least six months after the last dose. Live vaccines are generally avoided during and for several months after therapy due to safety risks and poor immune response.
Antivirals can disrupt live vaccines
While most antivirals do not directly suppress the immune system, some can block the replication of live vaccine viruses, lowering their effectiveness. Influenza antivirals like oseltamivir, zanamivir, peramivir, and baloxavir marboxil pose the biggest concern, particularly with the live attenuated influenza vaccine (LAIV) given as a nasal spray.
Related: Canadian plasma clinic halts collections amid scrutiny
Federal guidance advises avoiding LAIV within 48 hours after stopping oseltamivir or zanamivir, five days after peramivir, and 17 days after baloxavir. If antiviral treatment begins shortly after LAIV, revaccination with an inactivated flu shot may be necessary. Pharmacists administering flu vaccines should routinely ask about recent antiviral use to prevent these issues.
Pharmacists as the front line
With more patients starting biologics, immunosuppressants, and specialty drugs, pharmacists must screen for drug-vaccine interactions during medication reviews. Proactive discussions with prescribers and patients can help schedule vaccines at the best time—often before treatment begins—to maximize protection while minimizing risks.
Their role has grown in importance. A 2023 guidance from the American College of Rheumatology noted that patients with rheumatic and musculoskeletal diseases often require customized vaccine schedules. Pharmacists can identify these needs early, a principle that also applies to transplant recipients, cancer patients, and others on long-term immune-modifying therapies.
For now, the approach is straightforward: review the medication list, consider timing, and avoid assuming a standard vaccine schedule will work. The risks—preventable infections in already vulnerable patients—are too serious to ignore.
